What is Mustbio?
Mustbio is at the forefront of cancer treatment innovation, specializing in the creation of targeted therapeutics. The company leverages cutting-edge multi-specific and multi-antibody platform technologies to engineer treatments that bolster the immune system's capacity to combat tumors. These therapies are designed for enhanced safety and efficacy, aiming to overcome common challenges in cancer treatment such as resistance and limited effectiveness in specific tumor types. With a strong emphasis on research-driven development, Mustbio's portfolio includes novel immuno-cytokines and antibody-based treatments, positioning it as a key player in the advancement of next-generation immunotherapy.
How much funding has Mustbio raised?
Mustbio has raised a total of $23.5M across 1 funding round:
Series C
$23.5M
Series C (2026): $23.5M with participation from Ahn-Gook Pharmaceutical, SHINHAN CAPITAL, Korea Investment Partners, WONIK Investment Partners, Premier Partners, Korea Development Bank, and Partners Investment
Key Investors in Mustbio
Ahn-Gook Pharmaceutical
Ahn-Gook Pharmaceutical is a Korean pharmaceutical company with a broad product portfolio including respiratory, gastrointestinal, and anti-inflammatory agents, indicating a strategic interest in therapeutic advancements.
SHINHAN CAPITAL
Shinhan Capital is a comprehensive credit financial company that provides a wide range of services including facility lease, installment financing, and structured finance, suggesting a role in financing the company's growth and operational expansion.
Korea Investment Partners
Korea Investment Partners operates in the Photography Studio industry and has a revenue between $1M-$5M, which is unusual for a typical VC investor in this sector. This may indicate a diversified investment strategy or a data anomaly.
What's next for Mustbio?
The substantial enterprise-level investment in Mustbio signals a critical growth phase, likely enabling the company to accelerate its research and development pipeline, expand clinical trials, and potentially scale its manufacturing capabilities. This strategic financing will be instrumental in advancing its innovative immuno-oncology therapies through regulatory pathways and towards market commercialization. The backing from a diverse group of investors, including pharmaceutical companies and venture capital firms with a focus on healthcare and technology, suggests strong confidence in Mustbio's technology and its potential to disrupt the cancer treatment landscape.
See full Mustbio company page
